Large unilamellar and oligolamellar vesicles are formed when an aqueous buffer is introduced into a mixture of phospholipid and organic solvent and the organic solvent is subsequently removed by evaporation under reduced pressure. These vesicles can be made from various lipids or mixtures of lipids and have aqueous volume to lipid ratios that are 30 times higher than sonicated preparations and 4 times higher than multilamellar vesicles. Most The use of phospholipid vesicles (liposomes) in biology and medicine, a promising new area of research (1), will depend to a large degree on technological improvements in the formation of vesicles of various sizes and properties. As more attempts are made to modify cellular physiology by introducing regulatory molecules into the cell or to improve chemotherapy in the whole animal, the need for a vesicle preparation that entraps a large percentage of the aqueous phase has become apparent.
romo ecular assemblies with high efficiency. Thus, this relatively simple technique has unique advantages for encapsulating valuable water-soluble materials such as drugs, proteins, nucleic acids, and other biochemical reagents. The preparation and properties of the vesicles are described in detail.
The use of phospholipid vesicles (liposomes) in biology and medicine, a promising new area of research (1) , will depend to a large degree on technological improvements in the formation of vesicles of various sizes and properties. As more attempts are made to modify cellular physiology by introducing regulatory molecules into the cell or to improve chemotherapy in the whole animal, the need for a vesicle preparation that entraps a large percentage of the aqueous phase has become apparent.
The original liposome preparations of Bangham et al. (2) , consisting of multilamellar vesicles (MLV), have been admirably suited in defining many membrane properties (3, 4) and were the basis for the development of the sonicated unilamellar vesicles (SUV) (5) . However, both preparations show a relatively low volume of entrapped aqueous space per mole of lipid and restricted ability to encapsulate large macromolecules. This is because in MLV most of the lipid is participating in the internal lamellae, and the close apposition of the adjacent concentric bilayers restricts the internal water space. In SUV, which are single-compartment vesicles, the ratio of surface area to encapsulated volume is so large that only a small aqueous volume per mole of lipid can be attained. Attempts to circumvent these shortcomings (6) (7) (8) have been only partially successful. The ethanol injection method produces vesicles of about the same size as SUV with the same shortcomings. The ether infusion technique produces large unilamellar vesicles with high captured volumes per mole of lipid, but the efficiency of encapsulation is relatively low. Other useful techniques for preparing large volume vesicles either use specialized conditions (9) or are restricted to a single phospholipid (10) . Methods based upon solvent evaporation have been attempted in the past but have resulted in the formation of multilamellar vesicles (6, 11, 12) . A method designed to form asymmetric vesicles by centrifugation of a suspension of dense aqueous inverted micelles through an organic solvent/water interface has been reported (13) . The report indicated that the internal volume was small and the vesicles themselves relatively unstable (13) . Techniques based upon the removal of detergents-yield vesicles slightly larger than SUV (14) . These are suitable for membrane reconstitution experiments but, like the SUV, fail to encapsulate the aqueous phase efficiently. Recently a method that combines detergent dialysis and solvent evaporation has been described (15) . This technique leaves an equal weight of detergent per phospholipid in the resulting vesicles, making them unsuitable for many biological applications (15) .
Thus, no method has been described that can produce vesicles with the following desirable properties: (i) the ability to entrap a large percentage of the aqueous material presented; (ii) a high aqueous space-to-lipid ratio; and (iii) widely variable chemistry of the lipid components. We were particularly concerned with the first characteristic and reasoned that if total encapsulation of the material of interest could be achieved in an "inverted" micelle within an organic solvent, subsequent removal of the organic solvent might result in a high encapsulation. We have developed conditions that not only achieve a high percentage of encapsulation, but also produce vesicles with a large aqueous space-to-lipid ratio. This report describes the method and characteristics of the vesicles produced by the reverse-phase evaporation technique.
MATERIALS AND METHODS
Lipids and Other Materials. Cholesterol and palmitic acid were purchased from A. B. Fluka (Buch, Switzerland). Phosphatidylcholine (PtdCho), phosphatidylglycerol (PtdGro), and phosphatidylserine (PtdSer) werespurified from egg yolk and bovine brain as described (16) . Phosphatidic acid and dipalmitoyl phosphatidylcholine (Pal2PtdCho) were synthesized as reported (16) . All above lipids were finally purified on silicic acid columns, shown to be pure by thin-layer chromatography (17) , and stored in chloroform in sealed ampules under nitrogen at -50'C until use. Sphingomyelin (bovine brain) was purchased from K Preparation of Reverse-Phase Evaporation Vesicles (REV). Several phospholipids, either pure or mixed with other lipids such as cholesterol, long-chain alcohols, etc., can be used with similar results. The lipid mixture is added to a 50-ml round-bottom flask with a long extension neck, and the solvent is removed under reduced pressure by a rotary evaporator. The system is then purged with nitrogen and lipids are redissolved in the organic phase, in which the reversed phase vesicles will be formed. The solvents that have been most thoroughly investigated are diethyl ether and isopropyl ether, although halothane and trifluorotrichloroethane have been successfully used. When the lipid has low solubility in ether, chloroform or methanol can be added to increase their solubility. The detailed composition in each case is given in Table 1 .
The aqueous phase is added at this point, the system is kept continuously under nitrogen, and the resulting two-phase system is sonicated briefly (2-5 min) in a bath-type sonicator (Lab Supply T-80-80-IRS) until the mixture becomes either a clear one-phase dispersion or a homogeneous opalescent dispersion that does not separate for at least 30 min after sonication. The * Preparations 1-6 contained the encapsulated compound in 1.5 ml of 1/10 dilution of phosphate-buffered saline in distilled water with 5 ml of diethyl ether. Preparation 7 contained the encapsulated compound in 1.5 ml of 1/10 phosphate-buffered saline with 5 ml of isopropyl ether and 5 ml of chloroform, sonicated and evaporated at 450C. Preparations 8 and 9 (MLV and SUV) were prepared with ara C in 1/10 phosphate-buffered saline. t All preparations contained 66 Amol of total lipid per ml of aqueous phase, except for 2, 5, and 7, which contained 33 gmol/ml. Chol, cholesterol; SA, stearylamine.
Ratio of captured volume (Mgl) over weight (mg) of lipids. Captured volume was calculated from ara C encapsulation. § Based on ara C or sucrose capture; ara C or sucrose concentration was 3 mM in a 1/10 phosphate-buffered saline. Values for ara C are the mean ±SEM for at least three experiments; the values for sucrose capture are from a single experiment. ND, not done. Table 1 .
During evaporation of the solvent, the system froths. As the majority of the solvent is removed, the material first forms a viscous gel and subsequently (within 5-10 min) it becomes an aqueous suspension. At this point excess water or buffer can be added (but this is not necessary) and the suspension evaporated for an additional 15 min at 20'C to remove traces of solvent. When lipid mixtures lacking cholesterol are used at low concentrations (<7.5 timol of lipid per ml of aqueous phase) the gel phase may not be apparent since the system rapidly reverts to a lipid-in-water suspension. The preparation is then either dialyzed, passed through a Sepharose 4B column, or centrifuged to remove nonencapsulated material and residual organic solvent.
A typical preparation contains 33 ,mol of phospholipid and 33, mol of cholesterol in 1.0 ml of aqueous phase (phosphatebuffered saline) and 3 ml of solvent. These ratios must be maintained for maximal captures, but they can be scaled down or up without any change in the characteristics of the resulting vesicles. When vesicles are formed from Pal2PtdCho, an additional 3 ml of chloroform or 0.8 ml of methanol is added to the preparation, and the vesicles are allowed to remain at 450C for at least 30 min after evaporation of the solvent.
To determine the amount of encapsulated small molecules such as sodium, sucrose, or [3H]ara C, we dialyzed the vesicles overnight against 300 vol of phosphate-buffered saline (three changes) at 40C. Encapsulated iodinated proteins are separated from unencapsulated proteins by column chromatography on Sepharose 4B (1.5 X 42 cm). Encapsulated [3H]poly(A) can be separated from unencapsulated material by centrifugation at 100,000 X g for 30 min and resuspension of the pelleted vesicles in buffer (twice); the unencapsulated poly(A) remains in solution. Encapsulated 25S [32P]RNA is separated from unencapsulated material by first treating with RNase (50,ig) and alkaline phosphatase (10 ,ug) and then separating the encapsulated material from the hydrolyzed RNA on a Sepharose 4B column as above. The unencapsulated RNA is totally degraded by this procedure. The latency of alkaline phosphatase is established by measuring enzyme activity (19) in the presence and absence of 0.1% Triton X-100.
Freeze fracture and negative stain electron micrographs were prepared as described (6, 10) . The size of the vesicles was also determined by a dynamic light scattering technique as described (20) . Permeability experiments and preparation of SUV and MLV were carried out as described (6) . The nomenclature for the vesicle preparations adheres to recent recommendations (see p. 367 in ref. 1) .
RESULTS AND DISCUSSION The size and organization of the REV prepared from PtdGro/PtdCho/cholesterol (1:4:5 mole ratio) are illustrated in Fig. 1A . The inclusion of ferritin in the preparation can be seen as small (150 A) particles within the aqueous space both internally and externally. Smaller vesicles can be found within the interior aqueous space. Some vesicles appear to consist of a few concentric bilayers with a large internal aqueous space, while some appear as unilamellar. Electron micrographs of negative-stained vesicle preparations are shown in Fig. 1 (Fig. iC) . Dynamic light scattering yielded a mean value of 300 nm for PtdGro/PtdCho/cholesterol REV formed in phosphate-buffered saline and 450 nm for vesicles of the same composition formed in 1/10 phosphate-buffered saline, in good agreement with the negative stain. These vesicles could be filtered through an 800-nm Unipore polycarbonate filter without loss of contents, while filtration through a 400-nm Unipore filter released 25-30% of the encapsulated (ara C) material, producing a more uniform sized vesicle preparation. All the lipid was recovered in the filtrate after these filtrations. These data, in conjunction with the freeze-fracture (Fig. IA) and the negative-stain electron micrographs (Fig. 1B) , suggest that REV composed of PtdGro/PtdCho/cholesterol (1: 4:5) have a mean diameter between 200 and 500 nm. The size of the vesicles obtained by this method, however, seems to depend on the lipid composition and the solvent. REV formed by the standard technique and composed of PtdGro/PtdCho (1 :4) range in size from 100 to 300 nm when viewed by negative-stain electron micrographs (Fig. ID) . REV composed of PtdGro have a mean diameter of 200 nm (obtained by negative-stain electron microscopy).
The ability of REV to encapsulate ara C depends on the ionic strength of the buffer (Fig. 2) . As the ionic strength is increased, there is a decrease in both the percent encapsulation and the volume of encapsulated aqueous space per mole of phospholipid. High concentrations of sucrose, glycerol, or urea have no effect on the percentage encapsulation of ara C under similar conditions. We routinely encapsulate 30-45% of ara C from solutions containing 84 mg/ml in 15 mM NaCl buffer.
Varying the lipid concentration brings about an increase in the amount of capture up to a maximum of about 45% in 150 PtdGro/PtdCho/cholesterol (1/4/5). REV were formed with 100 gmol of total lipid in 5 ml of diethyl ether and 1.5 ml of the appropriate ionic strength NaCl buffer containing 3 mM ara C.
mM NaCl (Fig. 3) . Although the percentage of ara C encapsulated decreases with decreasing total lipid, the aqueous volume per mole of phospholipid is increased. It is 13. Although we have not determined the amount of solvent remaining in REV after an overnight dialysis, Deamer (21) has investigated this in vesicles prepared by the ether infusion technique and could not detect any ether in the vesicles after dialysis. Examination of the permeability properties of REV to sodium and ara C reveals a similarity to previous studies on MLV and SUV for these compounds (Table 2) (6, 22) .
The utility of these vesicles in entrapping various compounds is illustrated in Table 3 . To achieve maximal encapsulation of aqueous space it is necessary to use a buffer of low ionic strength. Alkaline phosphatase was totally latent when encapsulated in this way. To observe activity it was necessary to solubilize the REV with 1% Triton X-100. The aqueous fluorescent probe carboxyfluorescein remained highly quenched when encapsulated in REV, but underwent a 55-fold enhancement when the REV was lysed by 1% Triton X-100. In preliminary experiments the REV procedure appears suitable for the encapsulation of particulate material such as bacteria and mammalian chromosomes. The preparation contained the compound to be encapsulated in 1.5 ml of either phosphate-buffered saline (PBS) or a 1/10 dilution of phosphate-buffered saline, 5 ml of diethyl ether, and 100 ,umol of total lipid. The concentrations of the encapsulated material were as follows: sodium, 0.15 M; carboxyfluorescein, 0.01 M; poly(A), 3 mg/ml; 25S RNA, 1 mg/ml; insulin, 1 mg/ml; and ferritin, alkaline phosphatase, albumin, and IgG, 10 mg/ml.
A schematic diagram of the processes that might be occurring during formation of REV is shown in Fig. 4 Values for this table were determined from the appropriate vesicle preparation described in Table 1 or for large unilamellar lipid vesicles (LUV) (10) . Values given are for unfiltered preparations, at 66 M4mol/ml. * Encapsulation efficiency for water-soluble, low molecular weight compounds. The ratio of the amount of material remaining with the vesicles after separation from the unencapsulated material to the amount of material present for the encapsulation times 100. t Captured volume per mg of lipid. The ratio of the equivalent volume of aqueous space containing the encapsulated compound to the weight of lipid in the preparation. Size range that included 90% of the vesicles; determined by negative-stain electron microscopy.
arrived at after systematic evaluation of the effect of various solvents and relative ratios of solvent/water/lipid. The system we are describing produces large (200-500 nm, mean diameter) uni-and oligolamellar vesicles from a variety of phospholipids and other lipids, with a high capture efficiency for various solutes and macromolecules and ease of preparation. Furthermore, the process can be easily scaled up to large volumes and the vesicles can be sterilized by passage through a 200-nm filter. A summary of the size ranges, internal volumes, and reported encapsulation efficiencies for different liposome preparations is given in Table 4 .
It is possible that exposure to organic solvents might denature proteins that are particularly labile under these conditions. Our experience with alkaline phosphatase indicates, however, that an appreciable (41%) amount of activity can be retained. Nucleic acids are often isolated in the presence of organic solvents such as phenol or ethanol. This technique might therefore be valuable for those interested in encapsulating either mRNA or DNA and introducing them into cells either in vitro or in vivo. In this regard previous attempts to encapsulate poly(I-C) in MLV (23) or in LUV (24) have resulted in only 5-10% encapsulation. A small virus has been encapsulated in LUV (25) with a 10% encapsulation efficiency, and a recent report has demonstrated a 5% entrapment of E. coli RNA in vesicles by the ether infusion technique (26) . For comparison, using the REV we have been able to encapsulate 43% of poly(A) and 40% of a 25S rRNA. This is almost a 10-fold improvement in the efficiency of encapsulation. Such results suggest that this simple method for forming large uni-and oligolamellar vesicles (REV) with high capture efficiency could be an important technique for the introduction of various pharmacological and biochemical agents into biological systems in vitro and in vivo.
